RedHill Biopharma (RDHL) Current Deferred Revenue (2022 - 2023)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

RedHill Biopharma (RDHL) has disclosed Current Deferred Revenue for 2 consecutive years, with $10.7 million as the latest value for Q4 2023.

• Quarterly Current Deferred Revenue fell 77.74% to $10.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2023, down 77.74% year-over-year, with the annual reading at $10.7 million for FY2023, 77.74% down from the prior year.
• Current Deferred Revenue for Q4 2023 was $10.7 million at RedHill Biopharma, down from $47.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $47.9 million in Q4 2022, with the low at $10.7 million in Q4 2023.

Peer Comparison